Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe Study Record Dates now shows 'Last Update Posted (Estimated)' with new dates (2025-11-14, 2025-12-02). The previous generic 'Last Update Posted' label was removed.SummaryDifference0.3%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the site-wide funding-status notice about government funding lapses, which previously informed users that data may be out of date and inquiries might be delayed. The page's study details and eligibility information remain unchanged.SummaryDifference0.4%

- Check42 days agoChange DetectedNo substantive content changes were detected; the page continues to present the study overview, eligibility criteria, and planned outcomes for the Pembrolizumab + Olaparib trial. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.